Fate Therapeutics Inc (NAS:FATE)
$ 3.76 0.1 (2.73%) Market Cap: 428.01 Mil Enterprise Value: 135.15 Mil PE Ratio: 0 PB Ratio: 1.01 GF Score: 58/100

Fate Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 10, 2021 / 03:00PM GMT
Release Date Price: $68.43 (-1.28%)
Michael Eric Ulz
Morgan Stanley, Research Division - Equity Analyst

Good morning, everyone, and thanks for joining us at the Morgan Stanley Healthcare Conference. I'm Mike Ulz, one of the biotech analysts here. And it's my pleasure to introduce Scott Wolchko, CEO; and Ed Dulac, CFO, from Fate Therapeutics.

Just as a quick reminder, the format for today is a fireside chat. So please feel free to submit a question through the portal if you have one, and we'll be sure to address it in our conversation.

But before we get started, I just need to read a quick disclaimer. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

Questions & Answers

Michael Eric Ulz
Morgan Stanley, Research Division - Equity Analyst

So with that, we can jump right into the Q&A. So Scott and Ed, thanks

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot